PRISModegib: the use of the PRISM test to assess the health-related quality of life of patients with locally advanced basal cell carcinoma undergoing Hedgehog pathway inhibitor therapy

Br J Dermatol. 2019 Aug;181(2):406-407. doi: 10.1111/bjd.17754. Epub 2019 May 6.

Authors

G Gualdi¹, R Moro¹, V Regina¹, S Caravello¹, P Monari¹, P G Calzavara-Pinton¹

Affiliation

¹ Department of Dermatology, ASST Spedali Civili di Brescia, Brescia, Italy.

PMID: 30737996
DOI: 10.1111/bjd.17754

No abstract available

Publication types

Letter

MeSH terms

Aged
Aged, 80 and over
Anilides / administration & dosage
Anilides / adverse effects*
Antineoplastic Agents / administration & dosage
Antineoplastic Agents / adverse effects*
Carcinoma, Basal Cell / complications
Carcinoma, Basal Cell / diagnosis
Carcinoma, Basal Cell / drug therapy*
Drug Administration Schedule
Drug-Related Side Effects and Adverse Reactions / diagnosis*
Drug-Related Side Effects and Adverse Reactions / etiology
Drug-Related Side Effects and Adverse Reactions / prevention & control
Female
Hedgehog Proteins / antagonists & inhibitors
Hedgehog Proteins / metabolism
Humans
Male
Pyridines / administration & dosage
Pyridines / adverse effects*
Quality of Life*
Severity of Illness Index
Skin Neoplasms / complications
Skin Neoplasms / diagnosis
Skin Neoplasms / drug therapy*

Substances

Anilides
Antineoplastic Agents
Hedgehog Proteins
HhAntag691
Pyridines